SCHEMBL5205225

SCHEMBL5205225

CCCNC(=O)Nc1ccc(Oc2ccnc3cc(OC)c(OC)cc23)cc1[N+](=O)[O-]

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 16/20 0.65
PDGFRA P16234 15/20 0.65
KIT P10721 3/20 0.56
LCK P06239 2/20 0.56
TEK Q02763 2/20 0.56
FLT1 P17948 2/20 0.56
FLT4 P35916 2/20 0.56
AURKA O14965 1/20 0.56
FGFR2 P21802 1/20 0.56
AXL P30530 1/20 0.56
MET P08581 3/20 0.53
RIPK2 O43353 1/20 0.51
STK10 O94804 1/20 0.51
ABL1 P00519 1/20 0.51
LYN P07948 1/20 0.51
RET P07949 1/20 0.51
PDGFRB P09619 1/20 0.51
BCR P11274 1/20 0.51
FGFR1 P11362 1/20 0.51
SRC P12931 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5824384 0.91 PDGFRA (0.60) KDRPDGFRAKITLCKTEK
SCHEMBL4469272 0.91 PDGFRA (0.62) KDRPDGFRAKITLCKTEK
SCHEMBL5824847 0.88 PDGFRA (0.59) KDRPDGFRAKITLCKTEK
SCHEMBL5824645 0.87 KDR (0.58) KDRPDGFRAKITFLT1FLT4
SCHEMBL5202500 0.87 KDR (0.75) KDRPDGFRAKITFLT1FLT4
SCHEMBL5202090 0.85 KDR (0.76) KDRPDGFRAKITLCKTEK
SCHEMBL5205528 0.85 KDR (0.75) KDRPDGFRAKITLCKTEK
SCHEMBL5825041 0.84 KDR (0.55) KDRPDGFRAKITLCKTEK
SCHEMBL5204259 0.83 KDR (0.81) KDRPDGFRAKITFGFR2AXL
SCHEMBL6227624 0.82 PDGFRA (0.77) KDRPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1384712-B1 Derivatives of N-((quinolinyl)oxy)-phenyl)-urea and N-((quinazolinyl)oxy)-phenyl)-urea with antitumor activity KIRIN BREWERY (JP) 2007-03-07 EP disclosed
US-20070027318-A1 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2007-02-01 US disclosed
US-7169789-B2 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2007-01-30 US disclosed
US-20040209905-A1 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2004-10-21 US disclosed
US-6797823-B1 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2004-09-28 US disclosed
EP-1384712-A1 Derivatives of N-((quinolinyl)oxy)-phenyl)-urea and N-((quinazolinyl)oxy)-phenyl)-urea with antitumor activity KIRIN BEER KABUSHIKI KAISHA (JP) 2004-01-28 EP disclosed
EP-1153920-B1 QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES KIRIN BREWERY (JP) 2003-10-29 EP disclosed
EP-1153920-A1 QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES KIRIN BEER KABUSHIKI KAISHA (JP) 2001-11-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027318-A1 Quinoline derivatives and quinazoline derivatives CYTH3, NQO2, NRAS KDR 2466/4885PDGFRA 3108/4885KIT 629/4885
US-20040209905-A1 Quinoline derivatives and quinazoline derivatives RABL3, NRAS, CYTH3 KDR 3106/4885PDGFRA 3103/4885KIT 866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.